Nebulized Beta Adrenergic Agonist Therapy for Lung Diseases
On September 10, 2007, CMS posted a National Coverage Determination
(NCD) for nebulized beta adrenergic agonist therapy for lung diseases. After examining the available
medical evidence, CMS determined that no NCD is appropriate at this time. and that section 1862(a)(1)(A)
reasonable and necessary decisions should continue to be made by local Medicare contractors through the
local coverage determination process or case-by-case adjudication.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: December 21, 2007
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.